To avoid such a problem, further studies are needed, e.g., developing a drug delivery system to carry a SPINK1 inhibitor specifically toward malignant tumor tissues, and elucidating the difference in molecular mechanism behind the expression of SPINK1 between normal pancreas tissue and malignant tumor tissue. Here, SPINK1 is linked to cancer.